News

The study being terminated involved patients with one copy of the F508del mutation and one copy of a mutation that results in minimal cystic fibrosis transmembrane conductance regulator

NeuroVive now holds approximately 10 percent of the shares in Isomerase. The overall aim with the acquisition is to strengthen the existing partnership and accelerate NeuroVive’s research and

These data further support the efficacy of BAREMSIS which has previously been shown to prevent PONV alone, and in combination with standard anti-emetics in pivotal Phase 3 prophylaxis

The Company plans to continue collecting and analyzing epidemiological data relating to OPANA ER. Endo's financial projections for 2016 did not assume approval of the sNDA. Endo executive

Gross proceeds were $45 million. Approximately 7.63 million shares of common stock were issued at a price of $5.90 per share. Cantor Fitzgerald & Co. acted as sole

The study published in the journal PLOS Computational Biology shows that flexible molecules, instead of rigid ones, as previously thought, can bind more effectively to the proteins causing

The clinical trials will be undertaken across Edinburgh and South Ayrshire. NHS Lothian consultant ophthalmic surgeon Baljean Dhillon is one of 300 doctors across 24 different countries taking part

Fexapotide has completed 2 long-term large Phase 3 BPH studies‎ in the U.S. No other new prostate drug injectable currently in development has previously succeeded in enrolling and

The new investment, which is part of preferred-stock financing, increased AstraZeneca’s stake in Moderna to 9%. The British drugmaker first invested in Moderna in 2013. The agreement signed